CSIMarket Company Name, Ticker, Industry, else..
 
Disc Medicine Inc   (NASDAQ: IRON)
 
Price: $70.9150 $-3.22 -4.350%
Day's High: $75 Week Perf: -10.49 %
Day's Low: $ 70.31 30 Day Perf: -12.01 %
Volume (M): 146,868 52 Wk High: $ 99.50
Volume (M$): $ 0 52 Wk Avg: $74.46
Open: $74.66 52 Wk Low: $40.00



 Market Capitalization (Millions $) 2,743
 Shares Outstanding (Millions) 39
 Employees 155
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -246
 Cash Flow (TTM) (Millions $) -38
 Capital Exp. (TTM) (Millions $) 0

Business Description


Disc Medicine Inc. is a biotechnology company that focuses on developing novel therapeutic treatments for patients with serious and debilitating diseases related to red blood cell disorders. The company specializes in finding innovative solutions for disorders that involve the dysregulation of iron metabolism, such as iron-refractory iron deficiency anemia (IRIDA) and beta-thalassemia. By utilizing cutting-edge research and technologies, Disc Medicine aims to provide breakthrough therapies that can significantly improve the quality of life for patients suffering from these conditions.


   Company Address: 321 Arsenal Street, Suite 101 Watertown 2472 MA
   Company Phone Number: 674-9274   Stock Exchange / Ticker: NASDAQ IRON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.83%    
JNJ   -3.42%    
LLY   -3.53%    
MRK   -5.04%    
REGN   -7.13%    
TEVA   -1.47%    
• View Complete Report
   



Clinical Study

Innovative Advances in CKD Management Insights from DISC-0974 Phase 1b Trial at ASN Kidney Week 2025

Published Mon, Oct 20 2025 9:56 AM UTC

CSIMarket.com Chronic Kidney Disease (CKD) is a global health challenge marked by progressive loss of kidney function over time, often culminating in significant morbidity and mortality. Anemia associated with CKD is a common complication, leading to decreased quality of life, cardiovascular events, and increased healthcare costs. The management of these patients is comple...
Product Service News

Strategic Advancements in Hematologic Treatment Disc Medicines Positive FDA Engagement and Financial Adjustment in t...

Published Tue, Jan 21 2025 12:58 PM UTC

: Disc Medicine, Inc. a pioneering clinical-stage biopharmaceutical firm, has recently reported encouraging outcomes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the APOLLO post-marketing confirmatory trial for bitopertin, targeting erythropoietic protoporphyria (EPP). Alongside the regulatory progress, a retrospective examination of t...
Financing Agreement

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. to Propel Clinical Advancements in Hematology.

Published Fri, Nov 8 2024 1:30 PM UTC

Disc Medicine Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for serious hematologic diseases, has recently announced a significant financial milestone that positions the company for sustained growth and innovation in the field. The company secured a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC...
Clinical Study

Disc Medicine Reveals Promising Clinical Advances Ahead of ASH Annual Meeting A Gamechanger in Hematology,

Published Tue, Nov 5 2024 2:00 PM UTC

Emerging Innovations in Hematologic Disease Treatment: A Spotlight on Disc Medicine Disc Medicine, Inc. a clinical-stage biopharmaceutical company operating in the niche of hematologic diseases, is making significant strides in both research and clinical development. As they prepare for their presentations at the 66th American Society of Hematology (ASH) Annual Meeting sch...
Clinical Study

Promising New Data for DISC-0974 at ASN Kidney Week A Potential Game Changer for Chronic Kidney Disease and Anemia

Published Fri, Oct 11 2024 12:00 PM UTC

Disc Medicine, Inc. a clinical-stage biopharmaceutical company, recently announced to present new clinical data from its ongoing Phase 1b trial of DISC-0974 at the 2024 American Society of Nephrology (ASN) Kidney Week. The trial focuses on patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia a population that has been significantly underserved ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 4.26
PEG (TTM) -

Financial Strength Current
Quick Ratio 44.03
Working Capital Ratio 44.53
Leverage Ratio (MRQ) 0.14
Total Debt to Equity 0.09
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -6.67 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 34.55 $
Book Value 16.65 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,586,374
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.